POSTER: TCL-163: Novel Use of Tagraxofusp-erzs/Elzonris in CD123-Positive Gamma/Delta Cutaneous T-Cell Lymphoma
Madhuvani Korlapati, Cara Kelley, Gisselle Pichardo, Sami Ibrahimi et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Sami Ibrahimi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
93Publications signalées
2662Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentCAR-T cell therapy researchCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchCNS Lymphoma Diagnosis and Treatment
Publications récentes
TCL-163: Novel Use of Tagraxofusp-erzs/Elzonris in CD123-Positive Gamma/Delta Cutaneous T-Cell Lymphoma
Madhuvani Korlapati, Cara Kelley, Gisselle Pichardo, Sami Ibrahimi et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ABCL-615: EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Christina Y. Lee, David Andorsky, Ralph Boccia, Adelba Torres Lopez et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-615: EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Christina Y. Lee, David Andorsky, Ralph Boccia, Adelba Torres Lopez et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Abstract A047: Final analysis of a Phase 1 study of ibrutinib dose-escalation in TEDDI-R with isavuconazole for relapsed or refractory primary DLBCL of the CNS
Rahul Lakhotia, Christopher Melani, T. N. Gavrilova, Jagan Muppidi et autres
0 citationsBlood Cancer Discovery
HSD118 HEALTHCARE RESOURCE UTILIZATION WITH RECOMBINANT ADAMTS13 IN PATIENTS WITH CONGENITAL TTP: RESULTS FROM A PHASE 3 RANDOMIZED CLINICAL TRIAL
Marie Scully, Paul Knöbl, Paul Coppo, Wolf Hassenpflug et autres
0 citationsValue in Health
EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Christina Y. Lee, David Andorsky, Ralph V. Boccia, Adelba Liz Torres et autres
0 citationsJournal of Clinical Oncology
Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis
Usama Qamar, Zeeshan Imtiaz, Muhammad Hassan Jan, Siddharth Agarwal et autres
0 citationsThe American Journal of Cardiology
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
Lara Stepan, Sahar Ansari, Jeremy Abramson, Abood Okal et autres
2 citationsJournal of Clinical Oncology
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6
David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, Fernando Vargas Madueno et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM
Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston et autres
1 citationBlood Advances
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Catherine Diefenbach, Opeyemi A. Jegede, Victoria Wang, Stephen M. Ansell et autres
4 citationsBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.